Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)26.72
  • Today's Change0.540 / 2.06%
  • Shares traded139.60k
  • 1 Year change+5.20%
  • Beta0.7689
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Haohai Biological Technology Co Ltd is a China-based company mainly engaged in the production and sale of biological products, medical hyaluronic acid and intraocular lenses, research and development of bioengineering and pharmaceuticals, and provision of related services. The ophthalmology business has covered cataract treatment, myopia prevention and control, refractive correction, ocular surface medication, and optometry materials such as intraocular lenses and orthokeratology lenses. Medical beauty and wound care products include hyaluronic acid dermal fillers, hyaluronic acid gel for skin and mucosal superficial tissue supplementation. Orthopedic products include orthopedic joint cavity viscoelastic supplements and others. Anti-adhesion and hemostasis products include medical chitosan (for anti-adhesion), medical sodium hyaluronate gel and collagen sponge. The Company mainly conducts its businesses in domestic and foreign markets.

  • Revenue in HKD (TTM)2.92bn
  • Net income in HKD448.76m
  • Incorporated2007
  • Employees2.16k
  • Location
    Shanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
  • Phone+86 2 152293555
  • Fax+86 2 152293558
  • Websitehttps://www.3healthcare.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lepu Scientch Mdcl Tchnlgy Shnghi Co Ltd625.47m325.46m5.67bn374.0017.412.5415.839.060.93860.93861.806.450.24940.83236.061,991,946.0012.987.8314.899.2887.2389.1852.0335.625.03--0.000681.7844.4032.2862.2236.4582.59--
Yidu Tech Inc842.23m-100.74m6.41bn823.00--1.48--7.61-0.0954-0.09540.79624.120.159524.781.341,023,371.00-2.03-24.00-2.38-30.0834.4135.64-12.72-123.004.37--0.0321---11.415.0839.58--26.45--
Shanghai INT Medical Instruments Co Ltd1.04bn202.63m6.42bn2.01k25.192.5220.766.161.211.216.2212.070.38022.0511.49601,027.707.988.4610.149.8160.9960.3421.0024.360.96626.740.225324.3113.1724.3615.6312.6817.46--
BrainAurora Medical Technology Ltd193.08m-238.21m6.52bn174.00--21.68--33.77-0.1881-0.18810.15250.22140.3274--1.241,214,328.00-40.54---112.29--41.26---123.83-----10.130.6324--82.01--44.78------
China Isotope & Radiation Corp8.63bn480.38m6.59bn3.36k13.721.155.020.76331.501.5026.9917.990.51863.141.752,563,965.006.226.3112.9912.9948.2655.5411.9911.951.5168.900.27530.1614.1613.689.624.3311.8123.56
AK Medical Holdings Ltd1.57bn334.44m6.93bn1.00k20.652.2415.184.430.29880.29881.402.760.4111.062.661,642,495.008.778.0110.899.6959.2763.0121.3420.182.88--0.074722.5723.087.7650.420.51418.660.1873
MicroPort NeuroScientific Corp834.11m230.58m7.10bn522.0030.853.6223.938.510.39940.39941.443.400.35431.293.101,582,756.009.696.0411.237.0173.5874.5827.3616.604.71142.060.014135.6914.4432.9074.6340.172.49--
Zylox-Tonbridge Medical Technolgy Co Ltd1.02bn172.82m7.80bn875.0043.482.0836.377.670.53220.53223.1411.130.25731.40425.711,162,949.004.37-3.214.84-3.4471.4772.7516.98-21.205.16--0.0257--48.27175.65227.34--35.70--
LifeTech Scientific Corp1.50bn81.44m7.97bn1.27k91.821.8767.645.300.01870.01870.34610.92190.26150.69758.111,080,171.000.48166.080.58227.2672.6078.531.8420.722.09--0.13080.002.8814.28-15.5211.4715.11--
Xunfei Healthcare Technology Co Ltd909.84m-87.25m10.69bn928.00--10.71--11.75-0.7218-0.72187.538.260.44713.361.11998,731.30-4.80---11.06--54.37---10.73--1.49--0.3613--31.98--8.45------
Shanghai Haohai Biological Technology2.92bn448.76m11.07bn2.16k13.840.961617.133.791.931.9312.5527.790.3571.577.791,352,799.004.994.586.015.2669.5870.7113.9914.803.23--0.069642.371.7010.931.042.55-1.754.71
Angelalign Technology Inc2.43bn184.78m12.97bn3.54k69.603.4942.225.341.091.0914.3421.760.41956.808.48679,111.302.994.484.105.7362.5263.837.1311.672.69--0.1587--28.2323.5160.883.9814.40--
QingSong Health Corp1.41bn91.11m16.50bn205.00181.09--170.9011.690.44150.44156.84-6.21------7,236,434.00--------32.06--6.46------3.27--92.87---90.75------
Data as of Feb 13 2026. Currency figures normalised to Shanghai Haohai Biological Technology Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.63%Per cent of shares held by top holders
HolderShares% Held
Prudence Investment Management (Hong Kong) Ltd.as of 31 Dec 20241.97m5.40%
The Vanguard Group, Inc.as of 07 Jan 20261.59m4.36%
Dimensional Fund Advisors LPas of 08 Jan 2026391.84k1.07%
Vanguard Asset Management Ltd.as of 31 Dec 202568.86k0.19%
SSgA Funds Management, Inc.as of 08 Jan 202660.78k0.17%
Asset Management One Co., Ltd.as of 25 Nov 202446.20k0.13%
Rongtong Fund Management Co., Ltd.as of 30 Jun 202536.50k0.10%
Vanguard Fiduciary Trust Co.as of 30 Nov 202530.44k0.08%
Andbank Wealth Management SGIIC SAUas of 30 Jun 202526.03k0.07%
Dimensional Fund Advisors Ltd.as of 30 Nov 202522.40k0.06%
More ▼
Data from 31 Dec 2024 - 04 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.